Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Decheng Capital

Decheng Capital

Decheng Capital is a Shanghai, China-based venture capital firm that invests in early and growth stage companies in the life science industry.

Decheng Capital is a venture capital firm that provides capital to early- and growth-stage life science companies in China. They are a team of investment professionals with complementary expertise, a long history of working together, and a shared dedication to building successful companies that span the full spectrum of the life sciences industry. Their domain knowledge, access to innovative technologies, and ability to bring proven Western products to China make them the preferred partner for entrepreneurs, domestic and multinational companies, government agencies, and investors.

Decheng Capital is located in Shanghai and Silicon Valley and founded in 2012. With over $1 billion in capital under management, Decheng is poised to deliver returns for our investors and create value for our entrepreneur partners.


Decheng Capital's investments include Mynosys Cellular Devices, Hummingbird Bioscience, AnHeart Therapeutics, Baoyuan Biomedical, Bioheng, Luckin Coffee, Terns Pharmaceuticals, Polares Medical, and Mindstrong Health.

Their exited investments include Invitae, Luckin Coffee, Arcus Biosciences, ARMO BioSciences, GeneWEAVE and SentreHEART.


September 24, 2021
Cue Health, a Decheng Capital investment, launches a $200 million initial public offering (IPO).
October 9, 2020
Everest Medicines, a Decheng Capital investment, raises $451 million in an initial public offering in Hong Kong.
August 2020
Checkmate Pharmaceuticals, a Dcloses a $75 million initial public offering.

Invested in

Associated Investment Funds


Funding Rounds Participated In

Further Resources



Golden logo
By using this site, you agree to our Terms & Conditions.